Seattle Genetics Stocks List
|2019-10-22||AFMD||Expansion Pivot Sell Setup||Bearish Swing Setup|
|2019-10-22||AFMD||Fell Below 20 DMA||Bearish|
|2019-10-22||AFMD||50 DMA Resistance||Bearish|
|2019-10-22||AVEO||Narrow Range Bar||Range Contraction|
|2019-10-22||AVEO||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup|
|2019-10-22||CTIC||20 DMA Resistance||Bearish|
|2019-10-22||MEIP||50 DMA Support||Bullish|
|2019-10-22||PTLA||50 DMA Resistance||Bearish|
|2019-10-22||SGEN||Upper Bollinger Band Walk||Strength|
|2019-10-22||SGEN||Jack-in-the-Box Bullish||Bullish Swing Setup|
|2019-10-22||XCUR||Narrow Range Bar||Range Contraction|
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle), is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug Conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The companys' flagship product Adcetris (Brentuximab vedotin) is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program
to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Under the terms of the collaboration, Seattle Genetics has full commercialization rights to brentuximab vedotin in the United States and Canada. Takeda has exclusive rights to commercialize the product candidate in all other countries.
In addition to brentuximab vedotin, Seattle Genetics' product pipeline includes enfortumab vedotin, being co-developed with Astellas Pharma, tisotumab vedotin, being co-developed with Genmab, SGN-LIV1A, an ADC targeting LIV-1, and several immuno-oncology agents in phase 1 studies.
In January 2018, the business announced it would acquire Cascadian Therapeutics for $614 million.